GRI Bio, Inc.
GRIHealthcare|Biotechnology|US
$1.88
+0.33 (+21.29%)
DCF Value
$65.34
Tangible Book / Share
$5.70
Cash / Share
$6.06
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06331624 Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF | Idiopathic Pulmonary Fibrosis, IPF | P2 | Completed | 35 | RCT, Double-blind | Tazarotene (GRI-0621), Placebo |
| NCT02949375 Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease | Chronic Liver Disease | P2 | Terminated | 14 | RCT, Double-blind | Placebo Comparator, Active Comparator:4.5mg GRI-0621, Active Comparator: 6.0mg GRI-0621 |